iTeos Therapeutics to Participate in Investor Conferences
iTeos Therapeutics, Inc. (NASDAQ: ITOS), a pioneering clinical-stage biopharmaceutical company, has exciting news for investors. The management team has announced participation in two notable upcoming conferences that promise to showcase the company's innovative advancements in immuno-oncology therapeutics.
Conference Details
These conferences are excellent opportunities for investors to gain insights into iTeos' strategies and future prospects. The first event is the Annual Evercore HealthCONx Conference, scheduled for December 3. It will feature an engaging fireside chat, offering attendees a chance to understand the company’s vision.
Event Schedule
Investors will be able to attend one-on-one meetings that follow the fireside chat, designed to foster a more personal interaction between the company’s management and investors. The next day, on December 4, iTeos will participate in the Piper Sandler 36th Annual Healthcare Conference. This will also include a fireside chat and one-on-one meetings, making it a comprehensive platform for discussion.
Focus on Immuno-Oncology Therapeutics
iTeos Therapeutics is at the forefront of developing a new generation of immuno-oncology therapies aimed at enhancing the immune response to cancer. Their approach is rooted in a deep understanding of tumor immunology and the intricacies of immunosuppressive pathways, which may lead to groundbreaking treatments in the field.
Innovative Pipeline
The company’s innovative pipeline includes three clinical-stage programs targeting critical immunosuppressive pathways with a focus on the TIGIT/CD226 axis and the adenosine pathway. This strategic focus is crucial, as targeted therapies can revolutionize how we treat various cancers. iTeos’ commitment to research and development reflects its potential to significantly improve clinical outcomes.
Live Webcast and Replay
For those unable to attend the conferences in person, a live webcast of the presentations will be accessible in the Investors section of the company’s website. Furthermore, investors can look forward to archived replays available for about 30 days post-events, ensuring that no one misses out on vital information shared during these pivotal sessions.
About iTeos Therapeutics
Headquartered in Watertown, Massachusetts, with a research facility in Gosselies, Belgium, iTeos Therapeutics is dedicated to developing next-generation therapies. By leveraging cutting-edge technologies and pharmaceutical sciences, the company aims to restore immune functions impaired by cancer, potentially paving the way for future breakthroughs in treatment options.
Future Communication with Investors
Regular updates and information relevant to investors are routinely posted in the 'Investors' section of their website. This initiative underscores the company's commitment to transparency and ongoing communication with stakeholders.
Contact Information
For more inquiries, investors can reach out to Carl Mauch, the Investor Contact at iTeos Therapeutics, via email. Additionally, the media contact is also available for press-related inquiries, demonstrating the company’s open lines of communication.
Frequently Asked Questions
What are the upcoming investor conferences for iTeos Therapeutics?
iTeos will participate in the Annual Evercore HealthCONx Conference on December 3 and the Piper Sandler 36th Annual Healthcare Conference on December 4.
How can investors access the presentations from the conferences?
Investors can watch live webcasts of the presentations on the company's website, with archives available for approximately 30 days afterward.
What is the focus of iTeos Therapeutics?
The company focuses on the discovery and development of immuno-oncology therapeutics, aiming to enhance immune responses against cancer.
Where is iTeos Therapeutics headquartered?
iTeos Therapeutics is headquartered in Watertown, Massachusetts, with an additional research center in Gosselies, Belgium.
Who can investors contact for more information?
Investors can contact Carl Mauch for inquiries related to investor relations and can also reach out to the media department for press-related questions.
